Metabolomics Solutions for Clinical Drug Development Workflows
Failed Clinical Trials Cost You Time and Money
Metabolon’s Panels and Single Analyte Assays Deliver the Insights You Need
A Clearer Understanding of your Drug’s Mechanism of Action (MoA)
- Correlate changes in levels of highly annotated biochemicals with all other MoA and mechanistic data from your trial, from mid-translation through NDA submission
- Reveal pleiotropic effects from a majority of targets, including kinases, receptors, apoptosis factors, and immune modulators
- Provide a unique and comprehensive view of biochemical pathways to identify alterations that directly influence outcomes
See how Metabolon can advance your path to preclinical and clinical insights
Direct Evidence of Real-time Phenotypic Response
- Measure small-molecule biomarkers that are the result of a real-time response to your drug
- Provide deeper insights into precise biomarkers and MoA for disease instead of broad enzymatic activity that regulates a class of molecules
- Understand systemic alterations from drug treatment, providing a multi-organ snapshot of the effects of your drug in each patient
Reduce Noise with A Chemocentric Approach
Metabolon Global Discovery Panel leverages market-leading technology and the world’s largest biochemical reference library to quickly deliver quality insights.
Our chemocentric approach rapidly and efficiently removes noise and positively identifies metabolites. Our proprietary technology compares the generated data against our extensive metabolite library to isolate relevant metabolites in a matter of minutes. The result is accurate, reproducible, and actionable data delivering a higher resolution and quality beyond what’s possible with traditional ion-centric approaches.
Consultative Expertise
Metabolon Provides Solutions for Every Stage of Drug Development
Drug development is a lengthy process comprised of multiple steps, each with its own challenges and requirements. Metabolon has a solution for every step along the way.
- Cast a wide research net with our Global Discovery Panel, which enables the identification of 5,400+ metabolites across 70 major biochemical pathways.
- Once you’ve identified candidate biomarkers, use pre-developed or custom-targeted panels that deliver absolute quantification for research and biomarker applications.
We are ISO 9001, CAP and CLIA certified and can adhere to GCP/GCLP, where needed—so you can advance your biomarkers through clinical trials and commercial diagnostic testing.
Full Adherence to Research and Clinical Regulations
- All services and products adhere to ISO 9001:2015 standards.
- Targeted panels, including custom targeted panels, can be developed and validated to GCP/GCLP standards for Phase I-III clinical trials.
- Metabolon’s clinical diagnostics tests, such as the Quantose® Insulin Resistance test, adhere to CLIA, CAP, and New York State CLEP to support patient testing and clinical diagnostics.
We are ISO 9001, CAP and CLIA certified and can adhere to GCP/GCLP, where needed—so you can advance your biomarkers through clinical trials and commercial diagnostic testing.
How Metabolon Helps Improve Trial Design and Supports Trial Success
Channeling the Power of Metabolomics to Navigate Uncharted Regulatory Pathways for Microbiome Therapeutic Development
When an investigational microbiome therapeutic for preventing C. dificile
recurrence, SER-109, failed Phase II clinical trials, the company had to rethink its clinical trial design.
Using the Metabolon Discovery: Global Panel, the company was able to develop a more efficacious dosing strategy and redesign their clinical trial strategy. The troubleshooting worked—the Phase III clinical trial for SER-109 was a success. The company used Metabolon’s Good Clinical Practice (GCP)-validated targeted metabolomics panels to demonstrate mode of action and dose response of SER-109 during the trial.
Biomarkers for Neurogenetic Disease Progression
Translational research tools like the Metabolon Global Discovery Panel offer the ability to analyze the serum metabolomic profiles of other types of MPS or other neurological diseases. This will ultimately allow the identification of specific biomarkers (metabolites) for assessing disease progression, severity, and therapeutic outcome for these diseases.
The Impact of Probiotic Supplementation on Low Bone Mineral Density (BMD)
Metabolomics identified a number of potential biomarkers that link changes in the gut microbiota to changes in metabolomics that affect bone metabolism in aging women. Supplementation of the probiotic L. reuteri led to an increase in the serum levels of key amino acids that may regulate bone metabolism in older women.
GWAS and Metabolomics Profiling to Predict Antihypertensive Drug Responses
This study leveraged the power of genomics and metabolomics to study a complex multigenetic disease and provide further insight into possible treatment options for hypertension.
Interested in Further Studies?
Why Metabolon?
Once you see the full value of metabolomics, the only remaining question is who does it best? While many laboratories have metabolite profiling or analytical chemistry capabilities, comprehensive metabolomics technologies are extremely rare. Accurate, unbiased metabolite identification across the entire metabolome introduces signal-to-noise challenges that very few labs are equipped to handle. Also, translating massive quantities of data into actionable information is slow, if not impossible, for most because proper interpretation takes two things that are in short supply: experience and a comprehensive database.
Only Metabolon has all four core metabolomics capabilities
Coverage
Ability to interrogate thousands of metabolites across diverse biochemical space, revealing new insights and opportunities
Comparability
Ability to integrate the data from different studies into the same dataset, in different geographies, among different patients over time
Competency
Ability to inform on proper study design, generate high‐quality data, derive biological insights, and make actionable recommendations
Capacity
Ability to process hundreds of thousands of samples quickly and cost‐efficiently to service rapidly growing demand
Partner with Metabolon to access:
A library of 5,400+ known metabolites, 2,000 in human plasma, all referenced in the context of biochemical pathways
- That’s 5x the metabolites of the closest competitor
Unparalleled depth and breadth of experience analyzing and interpreting metabolomic data to find meaningful results
- 10,000+ projects with hundreds of clients
- 2,000+ publications covering 500 diseases, including numerous peer-reviewed journals such as Cell, Nature and Science
- Nearly 40 PhDs in data science, molecular biology, and biochemistry
Using our robust platform and visualization tools, our experts are uniquely able to tell you more about your molecule and develop assay panels to help you zero in on the results you need.
Related BioPharma Metabolomics Resources
Contact Us
Talk with an expert
Request a quote for our services, get more information on sample types and handling procedures, request a letter of support, or submit a question about how metabolomics can advance your research.
Corporate Headquarters
617 Davis Drive, Suite 100
Morrisville, NC 27560
References
1. Malinowska JM, Viant MR. Confidence in metabolite identification dictates the applicability of metabolomics to regulatory toxicology. Current Opinion in Toxicology. 2019/08/01/ 2019;16:32-38. doi:10.1016/j.cotox.2019.03.006
2. Frédérich M, Pirotte B, Fillet M, de Tullio P. Metabolomics as a Challenging Approach for Medicinal Chemistry and Personalized Medicine. Journal of medicinal chemistry. 2016;59 19:8649-8666.
3. Zgoda-Pols JR, Chowdhury S, Wirth M, Milburn MV, Alexander DC, Alton KB. Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol. Aug 15 2011;255(1):48-56. doi:10.1016/j.taap.2011.05.015
4. Wang G, Korfmacher WA. Development of a biomarker assay for 3-indoxyl sulfate in mouse plasma and brain by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. Jul 2009;23(13):2061-9. doi:10.1002/rcm.4111
5. Loomba R, Kayali Z, Noureddin M, et al. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. Nov 2018;155(5):1463-1473.e6. doi:10.1053/j.gastro.2018.07.027
